Home/Filings/4/0002043558-25-000003
4//SEC Filing

Rieger Jayson 4

Accession 0002043558-25-000003

CIK 0001660334other

Filed

Nov 24, 7:00 PM ET

Accepted

Nov 25, 7:00 PM ET

Size

11.2 KB

Accession

0002043558-25-000003

Insider Transaction Report

Form 4
Period: 2025-11-25
Rieger Jayson
DirectorCEO and President
Transactions
  • Purchase

    Series C Warrant (right to buy)

    2025-11-25+23,57723,577 total
    Exercise: $6.32Exp: 2030-11-25Common Stock (23,577 underlying)
  • Purchase

    Common Stock

    2025-11-25$4.24/sh+94,311$400,114182,593 total
Holdings
  • Common Stock

    (indirect: By Trust)
    230
  • Common Stock

    (indirect: By Children)
    15
  • Common Stock

    (indirect: By Trust)
    230
  • Common Stock

    (indirect: By Trust)
    230
Footnotes (4)
  • [F1]Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.
  • [F2]These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person is a co-trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
  • [F3]Immediately exercisable.
  • [F4]The reported securities are included within 94,311 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.

Issuer

Verrica Pharmaceuticals Inc.

CIK 0001660334

Entity typeother

Related Parties

1
  • filerCIK 0002043558

Filing Metadata

Form type
4
Filed
Nov 24, 7:00 PM ET
Accepted
Nov 25, 7:00 PM ET
Size
11.2 KB